Wart

Researchers are evaluating the effectiveness of two treatments, bleomycin injection and cryotherapy, for plantar warts Verruca Plantaris. This randomized controlled trial aims to compare how well these treatments work using dermoscopy, as well as assess their safety, economic impact, and effects on quality of life. The study includes adult participants aged 18 to 65 years with diagnosed plantar warts. Participants are randomly assigned to one of two groups the Bleomycin Group or the Cryotherapy Group. The bleomycin treatment involves injecting a diluted solution directly into the wart based on its size, while the cryotherapy treatment uses liquid nitrogen to freeze the wart twice with a 30-second interval. The effectiveness of each treatment is evaluated two weeks after the treatment ends. During the study, patients will undergo assessments including dermoscopic examination of the warts and photographic documentation of the lesions. Researchers will monitor the complete clearance rate of warts as the primary outcome. Safety and other impacts such as quality of life and cost will also be tracked. The total study duration and specific visit schedules are based on treatment and follow-up timelines ending in mid-2025.

Researchers are studying the safety and effectiveness of Candida antigen and bivalent HPV vaccine in treating common warts. The trial compares these treatments given alone or combined to see how well they clear warts and prevent recurrence. This is a Phase 2 randomized study involving patients with multiple warts. Participants are divided into three groups one receives Candida antigen injections directly into the largest wart, another receives bivalent HPV vaccine injections, and the third group receives both treatments together. Injections are given every two weeks for up to five sessions or until the warts clear. During the study, patients will be monitored for complete, partial, or no response to treatment over three months. Researchers will also follow up for six months after recovery to check for wart recurrence. Assessments include clinical evaluation of warts and treatment safety throughout the trial.

Researchers are evaluating the safety and effectiveness of YCANTH VP-102, a topical treatment, for people with common warts verruca vulgaris in a Phase 3 clinical trial called COVE-2. This study compares the active treatment to a placebo vehicle and includes participants aged 2 years and older who have at least one treatable common wart. The study aims to understand if YCANTH can clear all treatable warts by the end of the treatment period. The trial includes a Screening Period of up to 60 days, followed by a 75-day Treatment Period and a 63-day Follow-up Period. Participants receive topical applications of YCANTH VP-102 or a placebo every 21 days, up to four treatments. The study drug is applied to warts and a small area of surrounding skin, then covered with occlusive tape overnight. Wart paring may be done before application if needed. Warts are treated completely unless limited by the number of applicators. After each treatment, participants have in-person or telephone follow-ups to assess wart clearance and skin reactions. During the study, participants attend visits for dermatologic exams, wart measurements, and treatment assessments. Follow-up includes visual checks for complete wart clearance, monitoring of local skin reactions, adverse events, and medication use. Even if warts clear early, participants continue scheduled visits until the study ends. After this study, participants may join a long-term follow-up study to further evaluate YCANTH for up to 54 weeks. The primary outcome is the proportion of participants with complete clearance of all treatable warts by Day 84.

Idiopathic CD4 lymphocytopenia ICL is a disorder marked by low levels of CD4 T lymphocytes without an identifiable cause like HIV infection or other immunodeficiencies. This study aims to understand the natural history of ICL, examining changes in CD4 T cell counts and the development of infections, autoimmune diseases, or malignancies over time. Researchers also seek to explore the immune profile and possible genetic causes of ICL while providing standard care to manage infections. Participants include ICL patients as well as their blood relatives and household contacts. The study involves initial comprehensive evaluations including medical history, physical exams, various specialist consultations, blood tests for immune and genetic markers, urine tests, and infection assessments. Follow-up visits occur approximately every 12 months or more often if needed, continuing for at least 4 years and up to 10 years to monitor disease progression and immune status. During participation, patients undergo regular blood sampling to measure CD4 T cell counts and other immune parameters, along with evaluations for infections and autoimmune symptoms. Researchers also collect tissue samples and conduct genetic testing. The study measures outcomes such as CD4 levels, immune cell function, and correlations with infections or other health issues. Participants receive ongoing monitoring and treatment as appropriate, with the total involvement lasting from 4 to 10 years.

Researchers are evaluating the use of the human papillomavirus HPV vaccine for treating refractory cutaneous warts, which are common skin growths that can be painful, persistent, and difficult to treat. This randomized, double-blinded, placebo-controlled trial aims to determine if HPV vaccination can be an effective therapy for these stubborn warts, as current treatments often fail and warts can cause significant discomfort and distress. Participants will be randomly assigned to receive either the 9-valent HPV vaccine or a placebo. Injections are given as a 0.5-mL intramuscular dose at weeks 0, 4, and 20. The study includes 120 participants and follows them for 24 weeks to assess the vaccines effect on wart resolution and participants quality of life. During the trial, participants will have regular evaluations including assessments of their wart response at 4, 8, and 24 weeks after the first dose. Quality of life will be measured at multiple time points using the Skindex-16 questionnaire. Safety will be monitored throughout the study by recording any adverse events. The entire study duration for participants is 24 weeks, during which they will attend scheduled visits for injections and evaluations.

Researchers are investigating the use of hyperthermia treatment combined with microneedle patches to improve the treatment of viral warts. Hyperthermia involves raising the temperature of the skin to about 44 6C, which may help activate the bodys immune response to clear HPV-infected lesions. This study compares three groups hyperthermia alone, hyperthermia with a microneedle patch loaded with saline, and hyperthermia with a hydrogen peroxide microneedle patch to enhance treatment effects. Participants will be randomly assigned to receive one of the three treatments. Hyperthermia is applied to a selected wart for 30 minutes per session, with three sessions in the first week, two in the second, and two in the third week. The microneedle patches, either loaded with saline or hydrogen peroxide, are applied daily for one hour over six weeks. The study follows a randomized, parallel-group, assessor-blinded design with adaptive sample size adjustments based on interim results. During the study, participants will undergo treatment sessions and follow-up visits to monitor wart clearance and recurrence. Researchers will assess complete wart clearance rates, time to clearance, recurrence within six months, changes in wart size and number, pain during treatment, and any adverse events. The entire evaluation period includes treatment and six months of follow-up to gather comprehensive safety and efficacy data.

Researchers are evaluating whether injecting acyclovir or vitamin D3 directly into skin warts can help clear them in people aged 12 years and older. The study focuses on common, plantar, flat, and periungual warts and aims to determine which treatment is more effective and what side effects each may cause. This is a Phase 4 clinical trial comparing the two treatments in a randomized, parallel design. Participants receive injections of either acyclovir or vitamin D3 directly into the wart every 2 weeks for up to four sessions. The dose depends on the size of each wart. Two groups of 20 participants each will receive these treatments to compare their effects. Injections are given at baseline and repeated every 2 weeks during the treatment period. During the study, participants will have photographs taken of their warts before treatment and at each visit. Clinic visits will include measurements of wart size and number. Researchers will follow participants for up to 3 months after treatment to monitor for wart recurrence and any side effects. The main outcome measured is complete clearance of warts by week 8, along with early recurrence and safety outcomes.

Researchers are evaluating the long-term safety and effectiveness of a treatment called YCANTH also known as VP-102 or TO-208 for people with common warts who previously participated in related studies COVE-2 or COVE-3. This phase 3, open-label study aims to monitor side effects, including expected local skin reactions, and to assess how well repeated applications of YCANTH clear common warts over time. Participants with warts at the start of the study will receive YCANTH applied directly to each wart every 21 days, up to four additional treatments or until all warts clear. After clearance, participants will have observation visits every 42 days without treatment, but if new warts appear, treatment will resume. The study includes careful wart preparation, application of the drug with occlusive tape overnight, and monitoring of skin reactions. The entire study lasts approximately 294 days from parent study completion to the final visit on Day 378. Throughout the study, participants will attend treatment and observation visits where researchers will evaluate wart clearance, skin reactions, vital signs, and medication use. Detailed assessments include wart counts, photographic documentation for those who consent, and monitoring for adverse events. Participants must follow study instructions, including limiting certain water exposures after treatment, and will be observed until the study ends on Day 378.

This research aims to evaluate the effectiveness and safety of hyperthermia treatment for viral warts in special populations, including pregnant women, children, patients with autoimmune diseases, diabetes, and those on immunosuppressants after organ transplantation. Hyperthermia, a treatment using temperatures above normal body temperature, has shown promise in early studies by activating the bodys immune response to remove HPV infection lesions. Prior research by this group indicated a 45-55% cure rate with hyperthermia, with benefits like no trauma, low recurrence, and good tolerance, leading to inclusion in medical guidelines and device registration for national promotion. The study uses an infrared hyperthermia device set at 441C applied to lesions. Treatment involves three consecutive days of 30-minute sessions, followed by a break of 7-10 days, then two consecutive days of treatment, and subsequent sessions every 7-10 days. Lesion changes are assessed after 15 treatments to monitor the response to therapy. Participants will be monitored for cure and recurrence rates at three and six months, alongside rates of any adverse reactions. The study is conducted in multiple centers with real-world settings, focusing on this special population with viral warts. The total treatment and follow-up duration allow for assessing both short-term and longer-term outcomes of hyperthermia therapy for wart removal.

Researchers are evaluating the use of mild local hyperthermia combined with 3% hydrogen peroxide to treat viral warts, including common warts, plantar warts, and condyloma acuminatum. The study aims to assess the safety and effectiveness of warming the skin to 44C alongside applying hydrogen peroxide to clear wart lesions. This treatment approach is being compared to using either hyperthermia or hydrogen peroxide alone in a randomized clinical trial. Participants receive one of three treatments local hyperthermia alone applied to the largest wart, topical 3% hydrogen peroxide solution alone with simulated infrared light, or a combination where 3% hydrogen peroxide dressing is applied one hour before a 30-minute session of local hyperthermia at 44C. Hyperthermia treatments occur daily for three days, then twice weekly for three weeks, totaling seven sessions. Hydrogen peroxide is applied with cotton balls soaked in the solution as a dressing, and saline dressings are used during hyperthermia treatments. During the study, participants are monitored for wart clearance up to six months after treatment begins. Researchers measure complete clearance rates, time to clearance, and recurrence of warts. Secondary assessments include changes in wart size and number, pain during treatment sessions, adverse events, and patient satisfaction. Treatment sessions, follow-up visits, and safety monitoring are conducted over several weeks, with data collected at multiple intervals throughout the six-month period.